BridgeBio Pharma, Inc. (BBIO) vs Summit Therapeutics PLC (SMMT)
BridgeBio Pharma, Inc. and Summit Therapeutics PLC are both Biotechnology companies. BridgeBio Pharma, Inc. and Summit Therapeutics PLC are of similar size ($13.1B and $13.1B). BridgeBio Pharma, Inc. grew revenue faster over the last twelve months: 202.4% against −61.0%. Summit Therapeutics PLC has the higher net margin (0.00% vs −97.0%) and the higher return on invested capital (0.00% vs 0.00%). Across the 16 metrics below, BridgeBio Pharma, Inc. leads on 11 and Summit Therapeutics PLC on 5.
Valuation
Profitability
| Metric | BBIO | SMMT | Biotechnology median |
|---|---|---|---|
| Gross margin | 94.44% | 100.00% | 65.16% |
| Operating margin | (69.81%) | 0.00% | 0.00% |
| Net margin | (97.03%) | 0.00% | 0.00% |
| Free cash flow margin | (61.06%) | 0.00% | 0.00% |
| Return on equity | 32.31% | (192.50%) | (57.72%) |
| Return on assets | (60.23%) | (159.09%) | (49.22%) |
| Return on invested capital | 0.00% | 0.00% | 0.00% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack